Anti-VEGF PBS drug

Anti-VEGF remains most expensive PBS drug

The Australian government spent $55 million more on anti-VEGF macular disease therapies in 2020-21 compared to the previous year, with aflibercept (Eylea) maintaining its title as the costliest subsided drug in the country.
Read More